What biomarker testing is recommended for locally advanced Multiple Myeloma

Biomarker Testing for Multiple Myeloma

I'll walk you through the recommended biomarker and genetic testing that helps doctors understand your myeloma and plan treatment.

Essential Biomarker Tests at Diagnosis

According to the NCCN Guidelines for Multiple Myeloma (Version 3.2026), when you're diagnosed with myeloma, your care team should perform several key tests to measure disease burden and understand your specific cancer:

Blood Protein Markers

M Protein Testing (the hallmark of myeloma):

• Serum Protein Electrophoresis (SPEP) - measures the amount of abnormal M proteins in your blood
• Serum Immunofixation Electrophoresis (SIFE) - identifies which type of M protein you have (IgG, IgA, IgM, and which light chain: kappa or lambda)
• These tests are essential for both diagnosis and monitoring your response to treatment

Free Light Chain (FLC) Assay:

• Measures free light chains circulating in your blood
• Particularly important if your myeloma produces only light chains
• The FLC ratio is required to document complete response to treatment
• Helps assess kidney function impact

Immunoglobulin Levels:

• Measures total antibody levels (IgA, IgG, IgM)
• Shows if any antibody type is abnormally high or low

Kidney and Organ Function Markers

The NCCN Guidelines recommend these tests because myeloma commonly damages kidneys:

• Serum creatinine and BUN (kidney function)
• Creatinine clearance (calculated or measured)
• Serum calcium (myeloma can cause high calcium)
• Serum uric acid
• Albumin (protein level)
• Lactate dehydrogenase (LDH) - reflects tumor cell characteristics
• Beta-2 microglobulin - reflects tumor burden and prognosis
• NT-proBNP or BNP - heart function marker (some myeloma treatments affect the heart)

Critical Genetic/Chromosomal Testing

This is where the real prognostic power lies. According to NCCN Guidelines, Fluorescence In Situ Hybridization (FISH) testing on bone marrow plasma cells should examine for these specific abnormalities:

High-Risk Genetic Features

Your doctor should test for these chromosomal changes, as they significantly affect treatment planning:

| Genetic Finding | What It Means | |---|---| | del(17p13) | Deletion of chromosome 17 (loss of TP53 tumor suppressor gene) - HIGH RISK | | t(4;14) | Translocation between chromosomes 4 and 14 - HIGH RISK | | t(14;16) | Translocation between chromosomes 14 and 16 - HIGH RISK | | t(14;20) | Translocation between chromosomes 14 and 20 - HIGH RISK | | 1q21 amplification | Extra copies of chromosome 1q21 - associated with aggressive disease | | 1p deletion | Loss of part of chromosome 1p | | del(13) | Deletion of chromosome 13 | | t(11;14) | Translocation between chromosomes 11 and 14 - lower risk than others |

TP53 Mutation Testing

The NCCN Guidelines recommend Next-Generation Sequencing (NGS) to assess for TP53 mutations, which are associated with poor prognosis.

Why These Tests Matter for Your Care

Clinical Reasoning: Doctors use these biomarkers to:

1. Confirm diagnosis - M protein and light chains prove you have myeloma
2. Assess disease burden - How much cancer is present (measured by M protein levels and light chains)
3. Predict prognosis - Genetic abnormalities help determine if your myeloma is standard-risk or high-risk
4. Guide treatment selection - High-risk features may warrant more aggressive therapy combinations
5. Monitor treatment response - Serial testing shows if your M protein is decreasing (good response) or stable/increasing (progression)

Questions to Ask Your Oncology Team

Since biomarker results directly influence your treatment plan, consider asking:

1. "What is my M protein type and level, and what does this tell us about my disease?"
2. "Did my bone marrow biopsy include FISH testing for all the high-risk chromosomal abnormalities?"
3. "Do I have any high-risk genetic features, and how does this affect my treatment recommendations?"
4. "What is my free light chain ratio, and does this affect my kidney function?"
5. "How often will these biomarkers be tested during treatment, and what changes would indicate I need a different therapy?"

Important Context

According to the NCCN Guidelines, these biomarkers are "essential for staging" and help determine whether you have standard-risk or high-risk myeloma. This classification directly influences whether your doctors recommend certain drug combinations or whether you're a candidate for a hematopoietic cell transplant (stem cell transplant).

The good news: Even with high-risk features, modern multi-drug combinations and newer therapies like CAR T-cell therapy and bispecific antibodies have significantly improved outcomes for patients with aggressive myeloma.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.